A Phase 1 Study of ES414 in Patients Wtih Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2018
At a glance
- Drugs APVO-414 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Aptevo Therapeutics; Emergent Product Development Seattle
- 13 Mar 2018 According to an Aptevo Therapeutics media release, the company anticipates to complete enrollment of Phase 1 dosing cohorts in Q3 2018 and report preliminary data in Q4 2018.
- 09 Jan 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 09 Jan 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History